Incyte Corporation $INCY Shares Sold by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund lessened its holdings in Incyte Corporation (NASDAQ:INCY) by 6.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 222,839 shares of the biopharmaceutical company’s stock after selling 15,073 shares during the period. Illinois Municipal Retirement Fund’s holdings in Incyte were worth $18,899,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. denkapparat Operations GmbH raised its position in Incyte by 46.1% in the 2nd quarter. denkapparat Operations GmbH now owns 11,292 shares of the biopharmaceutical company’s stock valued at $769,000 after purchasing an additional 3,564 shares in the last quarter. LBP AM SA increased its stake in shares of Incyte by 33.6% during the third quarter. LBP AM SA now owns 238,705 shares of the biopharmaceutical company’s stock worth $20,245,000 after buying an additional 59,974 shares during the period. Rakuten Investment Management Inc. acquired a new stake in Incyte in the third quarter valued at approximately $14,646,000. Massachusetts Financial Services Co. MA raised its holdings in Incyte by 38.9% in the third quarter. Massachusetts Financial Services Co. MA now owns 387,605 shares of the biopharmaceutical company’s stock valued at $32,873,000 after acquiring an additional 108,645 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its stake in Incyte by 28.9% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 106,789 shares of the biopharmaceutical company’s stock worth $9,309,000 after acquiring an additional 23,954 shares during the last quarter. Institutional investors and hedge funds own 96.97% of the company’s stock.

Key Headlines Impacting Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Q4 revenue beat — Incyte reported $1.51B in Q4 sales (vs. ~$1.35B expected), reflecting 28% YoY growth driven by Jakafi and Opzelura; this supports near‑term top‑line momentum. Earnings Press Release
• Positive Sentiment: Earnings call emphasized pipeline beyond Jakafi — management highlighted growth drivers and progress on non‑Jakafi programs, which could ease long‑term reliance on the franchise. Earnings Call Transcript
• Positive Sentiment: HC Wainwright reiterates Buy with $135 target — a high‑conviction bullish call pointing to underappreciated pipeline value and long‑term revenue durability. HC Wainwright Buy Note
• Neutral Sentiment: Some voices argue the selloff is an overreaction to a guidance miss — analysis suggesting the weakness may be near‑term and that the stock could reprice if pipeline data and longer‑term growth prove resilient. Seeking Alpha: Overreaction
• Neutral Sentiment: Short‑interest reports in the feed show zero shares/NaN changes — data appears erroneous and should be treated with caution; no clear short squeeze signal. Article Title
• Negative Sentiment: EPS miss and weak 2026 revenue guide — Q4 EPS of $1.80 missed estimates (~$1.96) and management issued a soft full‑year net product revenue outlook, heightening concerns about replacing Jakafi sales as patents lapse. Reuters: Weak 2026 Forecast
• Negative Sentiment: Analyst downgrades/target cuts add pressure — Royal Bank of Canada cut its target to $92 (sector perform), signaling downside risk vs. current levels; other shops trimmed targets too. TickerReport: RBC Cut

Incyte Stock Down 1.2%

INCY opened at $98.84 on Thursday. Incyte Corporation has a one year low of $53.56 and a one year high of $112.29. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.13 and a current ratio of 3.23. The stock has a market capitalization of $19.40 billion, a P/E ratio of 15.42, a price-to-earnings-growth ratio of 0.60 and a beta of 0.82. The business’s 50-day simple moving average is $101.75 and its 200-day simple moving average is $93.81.

Incyte (NASDAQ:INCY) last announced its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.96 by ($0.16). The firm had revenue of $1.51 billion during the quarter, compared to analyst estimates of $1.35 billion. Incyte had a net margin of 25.03% and a return on equity of 26.34%. The firm’s revenue for the quarter was up 27.8% compared to the same quarter last year. During the same period last year, the company earned $1.43 earnings per share. Analysts anticipate that Incyte Corporation will post 4.86 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. Guggenheim raised shares of Incyte from a “neutral” rating to a “buy” rating and set a $125.00 price objective on the stock in a research report on Monday, November 3rd. The Goldman Sachs Group reiterated a “neutral” rating and set a $90.00 target price on shares of Incyte in a research note on Thursday, January 8th. Royal Bank Of Canada cut their price target on Incyte from $95.00 to $92.00 and set a “sector perform” rating on the stock in a research note on Wednesday. Wall Street Zen raised Incyte from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. Finally, Morgan Stanley set a $102.00 price objective on Incyte in a report on Wednesday. Nine research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Incyte presently has an average rating of “Hold” and a consensus target price of $103.94.

Insider Buying and Selling at Incyte

In related news, EVP Mohamed Khairie Issa sold 10,856 shares of the company’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $109.07, for a total value of $1,184,063.92. Following the completion of the sale, the executive vice president owned 66,132 shares in the company, valued at $7,213,017.24. This represents a 14.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael James Morrissey sold 54,008 shares of the firm’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $97.29, for a total transaction of $5,254,438.32. Following the transaction, the executive vice president directly owned 31,830 shares in the company, valued at $3,096,740.70. The trade was a 62.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 95,225 shares of company stock valued at $9,519,745. Insiders own 17.80% of the company’s stock.

Incyte Profile

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.